Page last updated: 2024-08-24

baicalin and 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide

baicalin has been researched along with 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (100.00)	2.80

Authors

Authors	Studies
Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V	1
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW	1

Reviews

1 review(s) available for baicalin and 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide

Article	Year
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4 Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2	2022

Other Studies

1 other study(ies) available for baicalin and 3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide

Article	Year
Perspectives on SARS-CoV-2 Main Protease Inhibitors. Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23 Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors	2021